ZNF224 and B-cell chronic lymphocytic leukemia: Here, to evaluate if ZNF224 could be an early molecular marker of disease progression and response to drug treatment we analyzed the expression levels of ZNF224 in B lymphocytes isolated from peripheral blood of 77 untreated CLL patients at different stages of disease and in a group of 28 treated patients (Supplementary Table S1).